查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1718092

治療性抗體市場（按形式、給藥途徑、來源、疾病領域、應用和最終用戶分類）—2025-2030 年全球預測

Antibody Therapeutics Market by Format, Route of Administration, Source, Disease Areas, Application, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2024年抗體治療市值將達2,580.1億美元，2025年成長至2,895.1億美元，複合年成長率為12.45%，到2030年將達到5,218.1億美元。

主要市場統計數據
基準年2024年 2580.1億美元
預計2025年 2895.1億美元
預測年份 2030 5218.1億美元
複合年成長率（%） 12.45%

治療性抗體是現代醫學最具活力的領域之一，結合了突破性的科學和無與倫比的臨床潛力。本執行摘要說明探討了近年來影響治療性抗體格局的市場演變、當前趨勢和競爭動態。生物技術的發展使得開發高度特異性的治療方法成為可能，徹底改變了各種疾病的治療方式。研究人員和產業專家越來越關注不僅能改善患者治療效果而且能改變監管和投資策略的創新。這些創新治療方法的研發歷程經過數十年的嚴謹研究、策略夥伴關係和快速技術進步，為下一代治療方法鋪平了道路。隨著市場向個人化醫療轉變，抗體片段、雙特異性抗體、單株抗體和多株抗體的策略部署將對臨床和商業性成功產生深遠的影響。此外，製造流程、給藥途徑和以患者為中心的創新等因素繼續推動該領域的發展。本摘要旨在為行業相關人員提供清晰、詳細的敘述，將科學創新與市場需求聯繫起來，使決策者能夠充分了解抗體療法的現狀和未來方向。

改變抗體治療市場

近年來，在突破性創新和不斷變化的市場需求的推動下，抗體治療領域發生了重大變化。透過新技術和創新製造方法的整合，傳統模式已被重塑，從而提高了治療藥物的功效和安全性。研究和開發工作越來越與精準醫療保持一致，從而可以採取有針對性的干涉措施，最佳化治療結果，同時最大限度地減少副作用。法律規範也正在發生重大變化，隨著當局意識到癌症、自體免疫疾病和其他慢性病等領域迫切需要及時的治療方案，新產品的推出也正在加速。該產業正在經歷整合和策略調整，現有企業採用敏捷的營運模式，新參與企業利用顛覆性技術。資金籌措機制和官民合作關係進一步凸顯了這個不斷變化的格局背後的動力。隨著臨床管道的擴大和治療方式的多樣化，相關人員被迫重新評估他們的價值提案、打入市場策略和長期投資觀點。這一變革時期期將以科學專家和市場策略家之間的積極合作為特徵，從而加速創新週期並提高轉換成功率。在這種動態的環境中，治療性抗體繼續處於醫學進步的前沿，並在競爭激烈、快節奏的行業中開闢新道路。

深入了解抗體療法的關鍵領域

對抗體治療市場的詳細評估揭示了對於理解當前趨勢和成長機會至關重要的細分見解。從格式角度研究市場動態時，可以觀察到涵蓋抗體片段、雙特異性抗體、單株抗體和多株抗體的詳細分析，每種抗體都對治療效果和臨床差異化有著獨特的貢獻。基於給藥途徑的評估清楚地比較了靜脈注射和皮下注射，強調了根據患者的便利性和生物有效性度選擇治療方法的重要性。此外，源分割增加了另一層洞察。透過檢查嵌合體、人類抗體和人源化抗體，我們可以評估分子工程如何影響免疫抗原性和治療結果。所涵蓋的疾病領域範圍廣泛——從自體免疫疾病和發炎性疾病到血液學、免疫學、神經病學、腫瘤學和骨病學——證明了基於抗體的治療方法在治療急性和慢性疾病方面的廣泛應用範圍。此外，市場根據應用（診斷、研究和治療）進行細分，以全面了解抗體技術如何改善臨床和實驗室環境。透過探索最終用戶的觀點，進一步豐富了細分分析，因為醫院、研究機構和專科診所各自透過其獨特的臨床實踐和籌資策略來塑造需求。這些全面的見解使相關人員能夠制定反映細微的市場現實和患者需求的策略。

目錄

第1章 引言

第2章調查方法

第3章執行摘要

第4章 市場概述

第5章 市場洞察

  • 市場動態
    • 驅動程式
      • 各種癌症和感染疾病率增加
      • 全球藥物研發活動日益活躍
      • 政府努力促進獲得抗體治療和療法
    • 限制因素
      • 對產品召回的擔憂
    • 機會
      • 治療性抗體的臨床開發進展
      • 新型抗體和治療方法的核准正在進行中
    • 任務
      • 各種治療方法療效不佳且有副作用
  • 市場區隔分析
    • 形式：抗體片段在癌症診斷和治療中的重要性日益增加
    • 應用：擴大治療性抗體在診斷上的應用，以實現有效的疾病管理
    • 給藥途徑：抗體藥物擴大靜脈注射
    • 來源：由於生物相容性，人類抗體的使用日益增多
    • 疾病領域：抗體藥物在感染疾病的應用日益增多
    • 最終用戶：抗體療法在醫院的應用不斷演變
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社會
    • 技術的
    • 合法的
    • 環境

第6章 抗體治療市場（依形式）

  • 抗體片段
  • 雙特異性抗體
  • 單株抗體
  • 多株抗體

第7章抗體治療市場（依給藥途徑）

  • 靜脈
  • 皮下

第8章抗體治療市場（依來源）

  • 嵌合體
  • 人類
  • 人性化

第9章抗體治療藥物市場（依疾病領域）

  • 自體免疫疾病與發炎性疾病
  • 血液學
  • 免疫學
  • 神經病學
  • 腫瘤學
  • 骨科

第 10 章抗體治療市場（依應用）

  • 診斷
  • 調查
  • 治療

第 11 章 抗體治療市場（依最終用戶分類）

  • 醫院
  • 研究機構
  • 專科診所

第 12 章：美洲抗體治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

13. 亞太地區抗體治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第 14 章歐洲、中東和非洲抗體治療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第15章競爭格局

  • 2024年市場佔有率分析
  • 2024年FPNV定位矩陣
  • 競爭情境分析
  • 戰略分析與建議

公司名單

  • AbbVie Inc.
  • AbCellera Biologics Inc.
  • Adaptimmune Therapeutics PLC
  • ADC Therapeutics SA
  • Aenova Holding GmbH
  • Almac Group Limited
  • Amgen Inc.
  • Antikor Biopharma
  • Argenx SE
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Baxter International Inc.
  • Bayer AG
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Biogen Inc.
  • BioNTech SE
  • Bristol-Myers Squibb Company
  • Confo Therapeutics
  • DH Life Sciences, LLC
  • DotBio Pte. Ltd.
  • Eli Lilly and Company
  • Emergent BioSolutions Inc.
  • Evonik Industries AG
  • F. Hoffmann-La Roche Ltd.
  • GE HealthCare Technologies, Inc.
  • Genmab A/S
  • GlaxoSmithKline PLC
  • Grifols, SA
  • Incyte Corporation
  • iTeos Therapeutics, Inc.
  • Johnson & Johnson Services, Inc.
  • Merck KGaA
  • Merus NV
  • MoonLake Immunotherapeutics AG
  • MorphoSys AG
  • Novartis AG
  • Novo Nordisk A/S
  • Numab Therapeutics AG
  • Pfizer Inc.
  • PharmAbcine Inc.
  • Pyxis Oncology, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • SAB Biotherapeutics, Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Thermo Fisher Scientific Inc.
  • TRIO Pharmaceuticals Inc.
  • UCB SA
  • Xencor, Inc.
Product Code: MRR-A42893A596E8

The Antibody Therapeutics Market was valued at USD 258.01 billion in 2024 and is projected to grow to USD 289.51 billion in 2025, with a CAGR of 12.45%, reaching USD 521.81 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 258.01 billion
Estimated Year [2025] USD 289.51 billion
Forecast Year [2030] USD 521.81 billion
CAGR (%) 12.45%

Antibody therapeutics represent one of the most dynamic segments of modern medicine, merging breakthrough science with unparalleled clinical potential. This executive summary offers an in-depth exploration of market evolution, current trends, and the competitive dynamics that have defined the antibody therapeutics landscape in recent years. Advancements in biotechnology have enabled the development of highly specific therapies, revolutionizing treatment methodologies across a range of diseases. Researchers and industry experts are increasingly focusing on innovations that not only improve patient outcomes but also transform regulatory pathways and investment strategies. The journey through these transformative therapies is underscored by decades of rigorous research, strategic partnerships, and rapid technological progress that have collectively paved the way for next-generation treatments. As the market shifts toward personalized medicine, the strategic deployment of antibody fragments, bispecific antibodies, monoclonal antibodies, and polyclonal antibodies exerts a profound influence on both clinical and commercial success. Moreover, factors such as manufacturing processes, route of administration, and patient-centric innovations continue to propel this field forward. This summary is designed to provide industry stakeholders with a clear, detailed narrative that bridges scientific innovation with market imperatives, ensuring that decision-makers remain well-informed about both the current state and the future direction of antibody therapeutics.

Transformative Shifts in the Antibody Therapeutics Landscape

Recent years have witnessed profound changes within the antibody therapeutics sector, driven by breakthrough innovations and evolving market needs. The traditional paradigm has been reshaped by the integration of novel technologies and innovative production methods that enhance the efficacy and safety profiles of therapies. Research and development efforts are increasingly aligned with precision medicine, allowing for targeted interventions that optimize treatment outcomes while minimizing side effects. Regulatory frameworks have also undergone significant modifications, expediting the introduction of new products as authorities acknowledge the critical need for timely therapeutic solutions in domains such as oncology, autoimmune disorders, and other chronic diseases. The industry has experienced consolidation and strategic realignments, with established companies embracing agile operational models and new entrants capitalizing on disruptive technologies. Funding mechanisms and public-private partnerships further underscore the momentum behind this evolving landscape. As clinical pipelines expand and the diversity of treatment modalities grows, stakeholders are compelled to reassess value propositions, market entry strategies, and long-term investment perspectives. This transformative period is marked by active collaboration between scientific experts and market strategists, leading to accelerated innovation cycles and improved translational successes. The resulting dynamic environment ensures that antibody therapeutics remain at the forefront of medical progress, carving new paths in a competitive and fast-paced industry.

Key Segmentation Insights into Antibody Therapeutics

A granular evaluation of the antibody therapeutics market reveals critical segmentation insights that are central to understanding current trends and growth opportunities. When studying market dynamics from a format perspective, one observes detailed analyses spanning antibody fragments, bispecific antibodies, monoclonal antibodies, and polyclonal antibodies, each contributing uniquely to therapeutic efficacy and clinical differentiation. Assessments based on the route of administration distinctly compare intravenous delivery with subcutaneous options, highlighting how patient convenience and bioavailability considerations drive therapeutic choices. Furthermore, the source segmentation adds another layer of insight. By considering chimeric, human, and humanized antibodies, analysts can evaluate how molecular engineering has impacted immunogenicity and therapeutic performance. The scope of disease areas covered-ranging from autoimmune and inflammatory diseases to hematology, immunology, neurology, oncology, and osteology-illustrates the broad applicability of antibody-based therapies in treating both acute and chronic conditions. In addition, the market is dissected along the lines of application, which spans diagnostics, research, and therapeutics, enabling a comprehensive understanding of how antibody technologies enhance both clinical and laboratory environments. The segmentation analysis is further enriched by examining the end-user perspective, with hospitals, research institutes, and specialty clinics each shaping demand through distinctive clinical practices and procurement strategies. These comprehensive insights empower stakeholders to tailor strategies that reflect nuanced market realities and patient needs.

Based on Format, market is studied across Antibody Fragment, Bispecific Antibody, Monoclonal Antibody, and Polyclonal Antibody.

Based on Route of Administration, market is studied across Intravenous and Subcutaneous.

Based on Source, market is studied across Chimeric, Human, and Humanized.

Based on Disease Areas, market is studied across Autoimmune & Inflammatory Diseases, Hematology, Immunology, Neurology, Oncology, and Osteology.

Based on Application, market is studied across Diagnostics, Research, and Therapeutics.

Based on End-User, market is studied across Hospitals, Research Institutes, and Specialty Clinics.

Regional Perspectives and Growth Opportunities in Antibody Therapeutics

The antibody therapeutics market is simultaneously influenced by global trends and localized demand, with each region presenting unique growth opportunities and challenges. Insights drawn from analyses across pivotal regions indicate that the Americas continue to lead in technology adoption and innovative clinical trials, driven by robust research infrastructure and strategic investments. Meanwhile, the combined regions of Europe, Middle East, and Africa exhibit a balanced approach to market penetration, where regulatory harmonization and diversified healthcare systems foster both innovation and accessibility. In the Asia-Pacific region, rapid economic growth, a surge in health awareness, and increased investment in biotechnology have spurred exponential market expansion, positioning it as a critical area of focus for companies seeking long-term growth. The regional insights provide an integrated view of factors such as regulatory environments, patient demographics, healthcare budgets, and infrastructural capabilities. These factors collectively determine market trajectories and influence the adoption of breakthrough therapeutic strategies. The interplay between regional economic trends and technological advancements creates a fertile ground for both incremental and transformative innovations in antibody therapeutics. A nuanced understanding of these geographic variances aids industry stakeholders in designing targeted investment strategies and localizing market entry plans that optimize regional strengths and address pertinent challenges effectively.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Insightful Strategies of Key Industry Players in Antibody Therapeutics

The competitive landscape of antibody therapeutics is characterized by a constellation of industry players that are actively shaping the future of healthcare through relentless innovation and strategic foresight. Leading organizations such as AbbVie Inc., AbCellera Biologics Inc., Adaptimmune Therapeutics PLC, and ADC Therapeutics SA have demonstrated a strong commitment to integrating next-generation technologies into their development pipelines. This trend is further reinforced by companies like Aenova Holding GmbH, Almac Group Limited, and Amgen Inc., which invest in precision manufacturing and advanced screening techniques to enhance product efficacy. Notably, strategic market responses by firms such as Antikor Biopharma, Argenx SE, and Astellas Pharma Inc. underscore the increasing importance of agile operational models and adaptive clinical strategies. Similarly, global giants like AstraZeneca PLC and Bayer AG, along with specialized entities including Baxter International Inc. and Becton, Dickinson and Company, are leveraging their expansive resources to drive forward innovations in therapeutic applications. The landscape is further diversified by players such as Bio-Rad Laboratories, Inc., Biogen Inc., and BioNTech SE, who are at the forefront of clinical research and have contributed significantly to the acceleration of novel therapies. Companies like Bristol-Myers Squibb Company, Confo Therapeutics, and DH Life Sciences, LLC, among many others, demonstrate that robust R&D investments combined with strategic collaborations are key drivers of market leadership. This assemblage of industry leaders reveals an ecosystem where established pharmaceutical titans and agile biotech innovators align to address complex clinical needs while capitalizing on emerging market trends. Their efforts not only drive competitive differentiation but also fundamentally influence how antibody therapeutics are developed and delivered globally.

The report delves into recent significant developments in the Antibody Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., AbCellera Biologics Inc., Adaptimmune Therapeutics PLC, ADC Therapeutics SA, Aenova Holding GmbH, Almac Group Limited, Amgen Inc., Antikor Biopharma, Argenx SE, Astellas Pharma Inc., AstraZeneca PLC, Baxter International Inc., Bayer AG, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Biogen Inc., BioNTech SE, Bristol-Myers Squibb Company, Confo Therapeutics, DH Life Sciences, LLC, DotBio Pte. Ltd., Eli Lilly and Company, Emergent BioSolutions Inc., Evonik Industries AG, F. Hoffmann-La Roche Ltd., GE HealthCare Technologies, Inc., Genmab A/S, GlaxoSmithKline PLC, Grifols, S.A., Incyte Corporation, iTeos Therapeutics, Inc., Johnson & Johnson Services, Inc., Merck KGaA, Merus N.V., MoonLake Immunotherapeutics AG, MorphoSys AG, Novartis AG, Novo Nordisk A/S, Numab Therapeutics AG, Pfizer Inc., PharmAbcine Inc., Pyxis Oncology, Inc., Regeneron Pharmaceuticals, Inc., SAB Biotherapeutics, Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Thermo Fisher Scientific Inc., TRIO Pharmaceuticals Inc., UCB S.A., and Xencor, Inc.. Actionable Recommendations for Industry Leaders in Antibody Therapeutics

Industry stakeholders must continuously adapt to the rapidly evolving landscape of antibody therapeutics by embracing innovation and fostering cross-disciplinary collaborations. A strategic emphasis on integrating advanced biotechnological methods can streamline production and enhance drug safety profiles. Leaders are advised to invest in scalable manufacturing processes that accommodate both current demands and future pipeline expansions. Furthermore, partnerships between industry, academia, and regulatory bodies are essential to fast-track clinical trials and address potential bottlenecks in product approvals. Given the diverse segmentation analysis-spanning format, route of administration, source, disease area, application, and end-user-it is critical to tailor marketing and distribution strategies accordingly. Embracing digital transformation and leveraging real-time data analytics can also provide a competitive edge by enabling more precise forecast and adaptive decision-making. Ultimately, proactive engagement in trend-setting research, technology transfer agreements, and comprehensive market assessments will not only secure a leading position in the antibody therapeutics market but also catalyze sustained innovation and growth in a competitive environment.

Conclusion: Navigating the Future of Antibody Therapeutics

The antibody therapeutics market continues to evolve at a rapid pace, driven by groundbreaking research and a dynamic competitive environment. The comprehensive insights presented in this executive summary underscore the critical significance of adaptive strategies, robust R&D investments, and targeted regional approaches that collectively shape market trajectories. The analysis of segmentation diverse in format, route of administration, source, disease area, application, and end-user reveals a system in which every component plays a vital role in meeting clinical demands. Moreover, regional evaluations highlight how localized market dynamics, regulatory frameworks, and healthcare spending patterns can influence the broader industry outlook. Equally noteworthy is the pivotal role of key industry players whose strategic initiatives have redefined competitive boundaries and set new benchmarks for innovation. As technological advancements continue to intersect with evolving therapeutic needs, stakeholders must remain vigilant, responsive, and forward-thinking. The journey ahead promises further transformative shifts that will undoubtedly redefine the contours of modern therapeutics. These insights collectively offer a strategic roadmap for decision-makers keen on navigating the complexities of the antibody therapeutics market while leveraging emerging opportunities for sustained growth.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidences of various cancers and infectious diseases
      • 5.1.1.2. Increasing number of drug discovery activities worldwide
      • 5.1.1.3. Government initiatives to promote access to antibody treatments and therapies
    • 5.1.2. Restraints
      • 5.1.2.1. Concerns over incidences of product recalls
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in the clinical development of antibody therapeutics
      • 5.1.3.2. Ongoing approvals for novel antibody therapies and treatments
    • 5.1.4. Challenges
      • 5.1.4.1. Insufficient efficacy and adverse effects associated with various treatments
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Format: Rising significance of antibody fragments for cancer diagnostics and treatment
    • 5.2.2. Application: Expanding application of antibody therapeutics in diagnostics sector for effective disease management
    • 5.2.3. Route of Administration: Growing usage of intravenous administration of antibody therapeutics
    • 5.2.4. Source: Increasing use of human antibodies due to its biocompatible nature
    • 5.2.5. Disease Areas: Proliferating use of antibody therapeutics for infectious diseases
    • 5.2.6. End User: Evolving usage of antibody therapeutics in hospitals
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Antibody Therapeutics Market, by Format

  • 6.1. Introduction
  • 6.2. Antibody Fragment
  • 6.3. Bispecific Antibody
  • 6.4. Monoclonal Antibody
  • 6.5. Polyclonal Antibody

7. Antibody Therapeutics Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Intravenous
  • 7.3. Subcutaneous

8. Antibody Therapeutics Market, by Source

  • 8.1. Introduction
  • 8.2. Chimeric
  • 8.3. Human
  • 8.4. Humanized

9. Antibody Therapeutics Market, by Disease Areas

  • 9.1. Introduction
  • 9.2. Autoimmune & Inflammatory Diseases
  • 9.3. Hematology
  • 9.4. Immunology
  • 9.5. Neurology
  • 9.6. Oncology
  • 9.7. Osteology

10. Antibody Therapeutics Market, by Application

  • 10.1. Introduction
  • 10.2. Diagnostics
  • 10.3. Research
  • 10.4. Therapeutics

11. Antibody Therapeutics Market, by End-User

  • 11.1. Introduction
  • 11.2. Hospitals
  • 11.3. Research Institutes
  • 11.4. Specialty Clinics

12. Americas Antibody Therapeutics Market

  • 12.1. Introduction
  • 12.2. Argentina
  • 12.3. Brazil
  • 12.4. Canada
  • 12.5. Mexico
  • 12.6. United States

13. Asia-Pacific Antibody Therapeutics Market

  • 13.1. Introduction
  • 13.2. Australia
  • 13.3. China
  • 13.4. India
  • 13.5. Indonesia
  • 13.6. Japan
  • 13.7. Malaysia
  • 13.8. Philippines
  • 13.9. Singapore
  • 13.10. South Korea
  • 13.11. Taiwan
  • 13.12. Thailand
  • 13.13. Vietnam

14. Europe, Middle East & Africa Antibody Therapeutics Market

  • 14.1. Introduction
  • 14.2. Denmark
  • 14.3. Egypt
  • 14.4. Finland
  • 14.5. France
  • 14.6. Germany
  • 14.7. Israel
  • 14.8. Italy
  • 14.9. Netherlands
  • 14.10. Nigeria
  • 14.11. Norway
  • 14.12. Poland
  • 14.13. Qatar
  • 14.14. Russia
  • 14.15. Saudi Arabia
  • 14.16. South Africa
  • 14.17. Spain
  • 14.18. Sweden
  • 14.19. Switzerland
  • 14.20. Turkey
  • 14.21. United Arab Emirates
  • 14.22. United Kingdom

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Scenario Analysis
    • 15.3.1. Numab Therapeutics, secured USD 55 million in funding, increasing its Series C round
    • 15.3.2. Alloy Therapeutics introduced a new licensing model for its ATX-Gx antibody discovery platform
    • 15.3.3. EQT Life Sciences EUR 54 million investment enhances ATB Therapeutics innovative antibody platform
    • 15.3.4. SystImmune and Bristol Myers Squibb Announce a Global Strategic Collaboration Agreement for the Development and Commercialization of BL-B01D1
    • 15.3.5. AbbVie and BigHat Biosciences Announce Research Collaboration to Leverage Artificial Intelligence and Machine Learning to Discover Next-Generation Therapeutic Antibodies
    • 15.3.6. AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
    • 15.3.7. MBrace Therapeutics Raises USD 85 Million Series B Financing to Advance Oncology Pipeline of Innovative Antibody Drug Conjugate Candidates
    • 15.3.8. Salipro Partners with Icosagen to Develop Monoclonal Antibody Therapies
    • 15.3.9. AbCellera, Incyte Partner on Therapeutic Antibodies in Oncology
    • 15.3.10. Japan Grants Patent for Bioarctic's Parkinson's Disease Antibody
    • 15.3.11. U.S. FDA Approves TALVEY, a First-in-Class Bispecific Therapy for the Treatment of Patients with Heavily Pretreated Multiple Myeloma
    • 15.3.12. Crossbow Therapeutics Debuts with USD 80 Million in Series A Financing to Advance Antibody Therapeutics
    • 15.3.13. Crossbow Therapeutics Debuts with USD 80 Million in Series A Financing to Advance Antibody Therapeutics
    • 15.3.14. Pyxis Oncology to acquire Antibody Therapeutics Company Apexigen
    • 15.3.15. Merck to Develop mAb Through USD 10.8 Billion Acquisition
    • 15.3.16. Genmab and argenx Enter Partnership to Advance Antibody Therapies in Immunology and Oncology
  • 15.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. AbCellera Biologics Inc.
  • 3. Adaptimmune Therapeutics PLC
  • 4. ADC Therapeutics SA
  • 5. Aenova Holding GmbH
  • 6. Almac Group Limited
  • 7. Amgen Inc.
  • 8. Antikor Biopharma
  • 9. Argenx SE
  • 10. Astellas Pharma Inc.
  • 11. AstraZeneca PLC
  • 12. Baxter International Inc.
  • 13. Bayer AG
  • 14. Becton, Dickinson and Company
  • 15. Bio-Rad Laboratories, Inc.
  • 16. Biogen Inc.
  • 17. BioNTech SE
  • 18. Bristol-Myers Squibb Company
  • 19. Confo Therapeutics
  • 20. DH Life Sciences, LLC
  • 21. DotBio Pte. Ltd.
  • 22. Eli Lilly and Company
  • 23. Emergent BioSolutions Inc.
  • 24. Evonik Industries AG
  • 25. F. Hoffmann-La Roche Ltd.
  • 26. GE HealthCare Technologies, Inc.
  • 27. Genmab A/S
  • 28. GlaxoSmithKline PLC
  • 29. Grifols, S.A.
  • 30. Incyte Corporation
  • 31. iTeos Therapeutics, Inc.
  • 32. Johnson & Johnson Services, Inc.
  • 33. Merck KGaA
  • 34. Merus N.V.
  • 35. MoonLake Immunotherapeutics AG
  • 36. MorphoSys AG
  • 37. Novartis AG
  • 38. Novo Nordisk A/S
  • 39. Numab Therapeutics AG
  • 40. Pfizer Inc.
  • 41. PharmAbcine Inc.
  • 42. Pyxis Oncology, Inc.
  • 43. Regeneron Pharmaceuticals, Inc.
  • 44. SAB Biotherapeutics, Inc.
  • 45. Sanofi S.A.
  • 46. Takeda Pharmaceutical Company Limited
  • 47. Thermo Fisher Scientific Inc.
  • 48. TRIO Pharmaceuticals Inc.
  • 49. UCB S.A.
  • 50. Xencor, Inc.

LIST OF FIGURES

  • FIGURE 1. ANTIBODY THERAPEUTICS MARKET MULTI-CURRENCY
  • FIGURE 2. ANTIBODY THERAPEUTICS MARKET MULTI-LANGUAGE
  • FIGURE 3. ANTIBODY THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 4. ANTIBODY THERAPEUTICS MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
  • FIGURE 17. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
  • FIGURE 19. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 21. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 23. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 25. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 26. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 27. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 28. ANTIBODY THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 29. ANTIBODY THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ANTIBODY THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ANTIBODY THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY FRAGMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY BISPECIFIC ANTIBODY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY POLYCLONAL ANTIBODY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY CHIMERIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HUMAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HUMANIZED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE & INFLAMMATORY DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HEMATOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY OSTEOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY RESEARCH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 42. ARGENTINA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 43. ARGENTINA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 44. ARGENTINA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. ARGENTINA ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 47. BRAZIL ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 48. BRAZIL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 49. BRAZIL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 50. BRAZIL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 51. BRAZIL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. BRAZIL ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 53. CANADA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 54. CANADA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 55. CANADA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 56. CANADA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 57. CANADA ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 58. CANADA ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 59. MEXICO ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 60. MEXICO ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 61. MEXICO ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 62. MEXICO ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 63. MEXICO ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. MEXICO ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 66. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 67. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 68. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 69. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 70. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 79. AUSTRALIA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 80. AUSTRALIA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 81. AUSTRALIA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 82. AUSTRALIA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 83. AUSTRALIA ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 84. AUSTRALIA ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. CHINA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 86. CHINA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 87. CHINA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 88. CHINA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 89. CHINA ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 90. CHINA ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. INDIA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 92. INDIA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 93. INDIA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 94. INDIA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 95. INDIA ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. INDIA ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. INDONESIA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 98. INDONESIA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 99. INDONESIA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 100. INDONESIA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 101. INDONESIA ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 102. INDONESIA ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. JAPAN ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 104. JAPAN ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 105. JAPAN ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 106. JAPAN ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 107. JAPAN ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 108. JAPAN ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 109. MALAYSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 110. MALAYSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 111. MALAYSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 112. MALAYSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 113. MALAYSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 114. MALAYSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 115. PHILIPPINES ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 116. PHILIPPINES ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 117. PHILIPPINES ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 118. PHILIPPINES ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 119. PHILIPPINES ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 120. PHILIPPINES ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 121. SINGAPORE ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 122. SINGAPORE ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 123. SINGAPORE ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 124. SINGAPORE ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 125. SINGAPORE ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 126. SINGAPORE ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH KOREA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH KOREA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH KOREA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH KOREA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 131. SOUTH KOREA ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 132. SOUTH KOREA ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 133. TAIWAN ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 134. TAIWAN ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 135. TAIWAN ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 136. TAIWAN ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 137. TAIWAN ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 138. TAIWAN ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 139. THAILAND ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 140. THAILAND ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 141. THAILAND ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 142. THAILAND ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 143. THAILAND ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 144. THAILAND ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 145. VIETNAM ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 146. VIETNAM ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 147. VIETNAM ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 148. VIETNAM ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 149. VIETNAM ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 150. VIETNAM ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 158. DENMARK ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 159. DENMARK ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 160. DENMARK ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 161. DENMARK ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 162. DENMARK ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 163. DENMARK ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 164. EGYPT ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 165. EGYPT ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 166. EGYPT ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 167. EGYPT ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 168. EGYPT ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 169. EGYPT ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 170. FINLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 171. FINLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 172. FINLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 173. FINLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 174. FINLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 175. FINLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 176. FRANCE ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 177. FRANCE ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 178. FRANCE ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 179. FRANCE ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 180. FRANCE ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 181. FRANCE ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 182. GERMANY ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 183. GERMANY ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 184. GERMANY ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 185. GERMANY ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 186. GERMANY ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 187. GERMANY ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 188. ISRAEL ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 189. ISRAEL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 190. ISRAEL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 191. ISRAEL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 192. ISRAEL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 193. ISRAEL ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 194. ITALY ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 195. ITALY ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 196. ITALY ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 197. ITALY ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 198. ITALY ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 199. ITALY ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 200. NETHERLANDS ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 201. NETHERLANDS ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 202. NETHERLANDS ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 203. NETHERLANDS ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 204. NETHERLANDS ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 205. NETHERLANDS ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 206. NIGERIA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 207. NIGERIA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 208. NIGERIA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 209. NIGERIA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 210. NIGERIA ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 211. NIGERIA ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 212. NORWAY ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 213. NORWAY ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 214. NORWAY ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 215. NORWAY ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 216. NORWAY ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 217. NORWAY ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 218. POLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 219. POLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 220. POLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 221. POLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 222. POLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 223. POLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 224. QATAR ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 225. QATAR ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 226. QATAR ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 227. QATAR ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 228. QATAR ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 229. QATAR ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 230. RUSSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 231. RUSSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 232. RUSSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 233. RUSSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 234. RUSSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 235. RUSSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 236. SAUDI ARABIA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 237. SAUDI ARABIA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 238. SAUDI ARABIA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 239. SAUDI ARABIA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 240. SAUDI ARABIA ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 241. SAUDI ARABIA ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 242. SOUTH AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 243. SOUTH AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 244. SOUTH AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 245. SOUTH AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 246. SOUTH AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 247. SOUTH AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 248. SPAIN ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 249. SPAIN ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 250. SPAIN ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 251. SPAIN ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 252. SPAIN ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 253. SPAIN ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 254. SWEDEN ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 255. SWEDEN ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 256. SWEDEN ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 257. SWEDEN ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 258. SWEDEN ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 259. SWEDEN ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 260. SWITZERLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 261. SWITZERLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 262. SWITZERLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 263. SWITZERLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 264. SWITZERLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 265. SWITZERLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 266. TURKEY ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 267. TURKEY ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 268. TURKEY ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 269. TURKEY ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 270. TURKEY ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 271. TURKEY ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 272. UNITED ARAB EMIRATES ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 273. UNITED ARAB EMIRATES ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 274. UNITED ARAB EMIRATES ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 275. UNITED ARAB EMIRATES ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 276. UNITED ARAB EMIRATES ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 277. UNITED ARAB EMIRATES ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 278. UNITED KINGDOM ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
  • TABLE 279. UNITED KINGDOM ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 280. UNITED KINGDOM ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 281. UNITED KINGDOM ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
  • TABLE 282. UNITED KINGDOM ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 283. UNITED KINGDOM ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 284. ANTIBODY THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • TABLE 285. ANTIBODY THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024